László Török

László Török

Auto-generated profile, based on publicly available information

László Török

Department of Traumatology, University of Szeged, Szeged, Hungary

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1996 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
LTL. Török
L. Török
LKL. Középessy
L. Középessy

29 September 2023 in Sports Medicine - Open
Verified
Journal Article
Open access
PDF file
GSGergő Szűcs
Gergő Szűcs
MPMárton Pipicz
Márton Pipicz
MSMárton Richárd Szabó
Márton Richárd Szabó
TCTamás Csont
Tamás Csont
LTLászló Török
László Török
CCCsaba Csonka
Csaba Csonka
There is a growing body of evidence showing the importance of physical activity against civilization-induced metabolic diseases, including type 2 diabetes (T2DM) and obesity. Eccentric contraction, when skeletal muscles generate force by lengthening, is a unique type of skeletal muscle activity. Eccentric contraction may lead to better power production characteristics of the muscle because eccentric contraction requires less energy and can result in higher tension. Therefore, it is an ideal tool in the rehabilitation program of patients. However, the complex metabolic effect (i.e., fat mass reduction, increased lipid oxidation, improvement in blood lipid profile, and increased insulin sensitivity) of the eccentric contraction alone has scarcely been investigated. This paper aims to review the current literature to provide information on whether eccentric contraction can influence metabolic health and body composition in T2DM or obesity. We also discussed the potential role of myokines in mediating the effects of eccentric exercise. A better understanding of the mechanism of eccentric training and particularly their participation in the regulation of metabolic diseases may widen their possible therapeutic use and, thereby, may support the fight against the leading global risks for mortality in the world.

30 April 2022 in Annals of Rehabilitation Medicine
Verified
Journal Article
Open access
PDF file
LTLászló Török
László Török
PJPéter Jávor
Péter Jávor
KTKatalin Török
Katalin Török
RRRárosi Rárosi
Rárosi Rárosi
PHPetra Hartmann
Petra Hartmann
Objective To compare the outcomes of a 6-month-long accelerated rehabilitation with a 12-month-long rehabilitation. There is no consensus on the optimal duration of rehabilitation after anterior cruciate ligament reconstruction (ACLR). Trends in the past decades have shifted towards accelerated programs, often resulting in a return to play (RTP) at 4–6 months, postoperatively. However, longer rehabilitation cycles have recently experienced renaissance due to a greater understanding of graft remodeling.Methods Adult athletes who underwent ACLR between 2015 and 2018 by the same surgeon were included and followed-up prospectively for 24 months. Participants were allocated into two groups based on their RTP (6 months vs. 12 months) and compared with graft elongation, reoperation rate, and sports career (quit or continue) outcomes.Results Fifty-four patients underwent accelerated rehabilitation and 92 completed conventional rehabilitation. The accelerated rehabilitation was significantly associated with graft elongation—the accelerated rehabilitation group (n=9) and the conventional rehabilitation group (n=0), p<0.001—and need for reoperation—the accelerated rehabilitation group (n=5) and the conventional rehabilitation group (n=1), p=0.026. Although the relationship between rehabilitation time and quitting competitive sports did not reach significance at 0.05 level (p=0.063), it was significant when p<0.1, thereby showing a clear trend.Conclusion Accelerated rehabilitation increased graft elongation risk. Knee laxity ≥3 mm measured at 6 months after ACLR should be accompanied by RTP time frame re-evaluation. Arthrometry checkups or routine magnetic resonance imaging shortly after RTP may be considered in cases of accelerated rehabilitation.

3 September 2021 in European Surgical Research
Verified
Journal Article
Open access
PDF file
PJPéter Jávor
Péter Jávor
ECEndre Csonka
Endre Csonka
EBEdina Butt
Edina Butt
FRFerenc Rárosi
Ferenc Rárosi
BBBarna Babik
Barna Babik
PHPetra Hartmann
Petra Hartmann
Purpose: The aim was to examine the predictive value of the hypovolemic shock classification currently accepted by the Advanced Trauma Life Support (ATLS) program over the previous one, which used only vital signs (VS) for patient allocation. The primary outcome was 30-day mortality; as secondary outcome, heart rate (HR), systolic blood pressure (SBP), Glasgow Coma Scale (GCS) and base deficit (BD) data were compared and investigated in terms of mortality prediction. Methods: Retrospective analysis at a level I trauma center between 2014 and 2019. Adult patients treated by trauma teams were allocated into severity classes (I–IV) based on the criteria of the current and previous ATLS classifications, respectively. The prognostic values for the classifications were determined with Fisher’s exact test and χ2 test for independence, and compared with the 2-proportion Z test. The individual variables were analyzed with receiver-operating characteristic (ROC) analyses. Results: A total of 156 patients met the inclusion criteria. Mortality was effectively predicted by both classifications, and there was no statistically significant difference between the predictive performances. According to ROC analyses, GCS, BD and SBP had significant prognostic values while HR change was ineffective in this regard. Conclusions: The currently used ATLS shock classification does not appear to be superior to the VS-based previous classification. GCS, BD and SBP are useful parameters to predict the prognosis. Changes in HR do not reflect the clinical course accurately; thus, further studies will be needed to determine the value of this parameter in trauma-associated hypovolemic-hemorrhagic shock conditions.

24 December 2021 in European Surgical Research
Verified
Journal Article
Open access
PJPéter Jávor
Péter Jávor
FRFerenc Rárosi
Ferenc Rárosi
THTamara Horváth
Tamara Horváth
LTLászló Török
László Török
PHPetra Hartmann
Petra Hartmann
Hemorrhage control often poses a great challenge for clinicians due to trauma-induced coagulopathy (TIC). The pathogenesis of TIC is not completely revealed; however, growing evidence attributes a central role to altered platelet biology. The activation of thrombocytes and subsequent clot formation are highly energetic processes being tied to mitochondrial activity, and the inhibition of the electron transport chain (ETC) impedes on thrombogenesis, suggesting the potential role of mitochondria in TIC. Our present study protocol provides a guide to quantitatively characterize the derangements of mitochondrial functions in TIC. One hundred eleven severely injured (injury severity score ≥16), bleeding trauma patients with an age of 18 or greater will be included in this prospective observational study. Patients receiving oral antiplatelet agents including cyclooxygenase-1 or adenosine diphosphate receptor inhibitors (aspirin, clopidogrel, prasugrel, and ticagrelor) will be excluded from the final analysis. Hemorrhage will be confirmed and assessed with computer tomography. Conventional laboratory markers of hemostasis such as prothrombin time and international normalized ratio will be measured and rotational thromboelastometry (ROTEM) will be performed directly upon patient arrival. Platelets will be isolated from venous blood samples and subjected to high-resolution fluororespirometry (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria) to evaluate the efficacy of mitochondrial respiration. Oxidative phosphorylation (OxPhos), coupling of the ETC, mitochondrial superoxide formation, mitochondrial membrane potential changes, and extramitochondrial Ca2+-movement will be recorded. The association between OxPhos capacity of platelet mitochondria and numerical parameters of ROTEM aggregometry will constitute our primary outcome. The relation between OxPhos capacity and results of viscoelastic assays and conventional markers of hemostasis will serve as secondary outcomes. The association of the OxPhos capacity of platelet mitochondria upon patient arrival to the need for massive blood transfusion and 24-h mortality will constitute our tertiary outcomes. Mitochondrial dysfunction and its importance in TIC are yet to be assessed for the deeper understanding of this common, life-threatening condition. Disclosure of mitochondria-mediated processes in thrombocytes may reveal new therapeutic targets in the management of hemorrhaging trauma patients, thereby leading to a reduction of potentially preventable mortality. The present protocol was registered to ClinicalTrials.gov on 12 August 2021, under the reference number NCT05004844.

27 December 2025 in Magyar Traumatológia Ortopédia Kézsebészet Plasztikai Sebészet
Verified
Journal Article
Closed access
LKLászló József Kisvári
László József Kisvári
ZMZoltán Péter Mészáros
Zoltán Péter Mészáros
ASAnna Szabó
Anna Szabó
ZBZoltán Bozóki
Zoltán Bozóki
LSLilla Sándor
Lilla Sándor
PHPetra Hartmann
Petra Hartmann
A nagy vérvesztéssel járó műtétek esetén a perfúziós elégtelenség korai felismerése elengedhetetlen, mivel a hipovolemiás sokk a vérzés következtében az egyik leggyakoribb, de megelőzhető halálok. A jelenleg alkalmazott hemodinamikai paraméterek, mint a vérnyomás és a szívfrekvencia, korlátozott prediktív értékkel bírnak. A kilélegzett metán (CH4) koncentrációjának mérése a mesenterialis perfúzió monitorozásának új lehetősége, mivel a vérvesztés elsődleges reakciója az arteria mesenterica superior (SMA) véráramlásának csökkenése. Az SMA által ellátott bélszegmens flórája pedig a kilélegzett metán elsődleges forrása. Célunk a kilélegzett CH4 változásának vizsgálata nagyízületi endoprotézis beültetésen átesett betegeknél. 2024.09.01. és 2024.10.31. között a Szegedi Tudományegyetem Traumatológiai és Ortopédiai Klinikáján prospektív kutatást végeztünk, amely során nagyízületi endoprotézis beültetett betegek kilélegzett CH4 koncentrációt vizsgáltuk pre- és posztoperatívan. A méréseket fotoakusztikus spektroszkóp (PAS) készülékkel végeztük. Ezen kívül nyomon követtük a műtéti vérveszteséget, az adminisztrált folyadékokat és a vitális paramétereket az aneszteziológiai dokumentáció alapján. 25 beteget vizsgáltunk meg (56% férfi, 44% nő, átlagéletkor: 66.12 ± 9.72év). A betegek 32%-a volt CH4-termelő. Az átlagos vérvesztés 262 ± 159.61 ml volt, a beadott krisztalloid mennyisége 747,83 ± 307,29 ml, a kolloid mennyisége pedig 521,42 ± 80,18 ml. A kilélegzett CH4 változása és a vérvesztés mértéke közötti összefüggés közepes pozitív volt (r = 0,57), de nem bizonyult statisztikailag szignifikánsnak (p = 0,1386). Eredményeinket a műtéti vérvesztés alacsony szintje és a kis elemszám korlátozza. Amennyiben nagyobb elemszámú vizsgálatok megerősítik ezeket az eredményeket, a CH4 valós idejű monitorozása hasznos lehet a vérvesztés korai felismerésében, és javíthatja a sürgősségi és műtéti ellátás minőségét.